LB Pharmaceuticals Enters Agreement to Sell 3.3 Million Shares to Institutional Investors

LB Pharmaceuticals entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such pre-funded warrant. LB Pharmaceuticals anticipates the gross proceeds from the private placement to be approximately $100M, before deducting any transaction-related expenses. The private placement is expected to close on or about February 6, subject to the satisfaction of customary closing conditions. The financing includes participation from new and existing institutional investors, including Balyasny Asset Management, Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners, and other investors. Leerink Partners, Piper Sandler and Stifel acted as placement agents for the private placement.